IPA vs. VIRX, DARE, APLM, APRE, ACXP, THTX, NRXP, BCTX, FBIO, and SPRB
Should you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Viracta Therapeutics (VIRX), Daré Bioscience (DARE), Apollomics (APLM), Aprea Therapeutics (APRE), Acurx Pharmaceuticals (ACXP), Theratechnologies (THTX), NRx Pharmaceuticals (NRXP), BriaCell Therapeutics (BCTX), Fortress Biotech (FBIO), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical preparations" industry.
Viracta Therapeutics (NASDAQ:VIRX) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Viracta Therapeutics received 19 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 72.22% of users gave Viracta Therapeutics an outperform vote.
Viracta Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 733.33%. ImmunoPrecise Antibodies has a consensus target price of $7.00, suggesting a potential upside of 509.60%. Given ImmunoPrecise Antibodies' higher probable upside, research analysts clearly believe Viracta Therapeutics is more favorable than ImmunoPrecise Antibodies.
Viracta Therapeutics has a net margin of 0.00% compared to Viracta Therapeutics' net margin of -60.23%. Viracta Therapeutics' return on equity of -26.54% beat ImmunoPrecise Antibodies' return on equity.
In the previous week, Viracta Therapeutics had 5 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 7 mentions for Viracta Therapeutics and 2 mentions for ImmunoPrecise Antibodies. Viracta Therapeutics' average media sentiment score of 1.43 beat ImmunoPrecise Antibodies' score of 0.89 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the news media.
Viracta Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.
ImmunoPrecise Antibodies has higher revenue and earnings than Viracta Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 7.4% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Viracta Therapeutics beats ImmunoPrecise Antibodies on 9 of the 16 factors compared between the two stocks.
Get ImmunoPrecise Antibodies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunoPrecise Antibodies Competitors List
Related Companies and Tools
